Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.

Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E, Cochet C, Schmid RS, Lo DC, Delhommel F, Oberholzer AE, Pearl LH, Carreaux F, Bazureau JP, Knapp S, Meijer L.

J Med Chem. 2012 Nov 8;55(21):9312-30. doi: 10.1021/jm301034u.

PMID:
22998443
2.

Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.

Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P, Lozach O, Babault L, Tahtouh T, Baratte B, Ogawa Y, Hagiwara M, Eisenreich A, Rauch U, Knapp S, Meijer L, Bazureau JP.

J Med Chem. 2011 Jun 23;54(12):4172-86. doi: 10.1021/jm200274d.

PMID:
21615147
3.

Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.

Naert G, Ferré V, Meunier J, Keller E, Malmström S, Givalois L, Carreaux F, Bazureau JP, Maurice T.

Eur Neuropsychopharmacol. 2015 Nov;25(11):2170-82. doi: 10.1016/j.euroneuro.2015.03.018.

PMID:
26381812
4.

Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.

Burgy G, Tahtouh T, Durieu E, Foll-Josselin B, Limanton E, Meijer L, Carreaux F, Bazureau JP.

Eur J Med Chem. 2013 Apr;62:728-37. doi: 10.1016/j.ejmech.2013.01.035.

PMID:
23454515
5.

cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer's disease.

Fant X, Durieu E, Chicanne G, Payrastre B, Sbrissa D, Shisheva A, Limanton E, Carreaux F, Bazureau JP, Meijer L.

Mol Pharmacol. 2014 Mar;85(3):441-50. doi: 10.1124/mol.113.090837.

6.

Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.

Jain P, Karthikeyan C, Moorthy NS, Waiker DK, Jain AK, Trivedi P.

Curr Drug Targets. 2014 May;15(5):539-50. Review.

PMID:
24568585
7.

Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.

Yadav RR, Sharma S, Joshi P, Wani A, Vishwakarma RA, Kumar A, Bharate SB.

Bioorg Med Chem Lett. 2015 Aug 1;25(15):2948-52. doi: 10.1016/j.bmcl.2015.05.034.

PMID:
26048785
8.

Mechanism of dual specificity kinase activity of DYRK1A.

Walte A, Rüben K, Birner-Gruenberger R, Preisinger C, Bamberg-Lemper S, Hilz N, Bracher F, Becker W.

FEBS J. 2013 Sep;280(18):4495-511. doi: 10.1111/febs.12411.

9.

Design of granulatimide and isogranulatimide analogues as potential Chk1 inhibitors: Study of amino-platforms for their synthesis.

Lavrard H, Rodriguez F, Delfourne E.

Bioorg Med Chem. 2014 Sep 1;22(17):4961-7. doi: 10.1016/j.bmc.2014.06.028.

PMID:
25047935
10.

A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.

Coutadeur S, Benyamine H, Delalonde L, de Oliveira C, Leblond B, Foucourt A, Besson T, Casagrande AS, Taverne T, Girard A, Pando MP, Désiré L.

J Neurochem. 2015 May;133(3):440-51. doi: 10.1111/jnc.13018.

11.

Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.

Schmitt C, Kail D, Mariano M, Empting M, Weber N, Paul T, Hartmann RW, Engel M.

PLoS One. 2014 Mar 27;9(3):e87851. doi: 10.1371/journal.pone.0087851.

12.

New leukotriene B4 receptor antagonist: leucettamine A and related imidazole alkaloids from the marine sponge Leucetta microraphis.

Chan GW, Mong S, Hemling ME, Freyer AJ, Offen PH, DeBrosse CW, Sarau HM, Westley JW.

J Nat Prod. 1993 Jan;56(1):116-21.

PMID:
8383730
13.

Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.

Rothweiler U, Eriksson J, Stensen W, Leeson F, Engh RA, Svendsen JS.

Eur J Med Chem. 2015 Apr 13;94:140-8. doi: 10.1016/j.ejmech.2015.02.035.

PMID:
25768698
14.

Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.

Cozza G, Sarno S, Ruzzene M, Girardi C, Orzeszko A, Kazimierczuk Z, Zagotto G, Bonaiuto E, Di Paolo ML, Pinna LA.

Biochim Biophys Acta. 2013 Jul;1834(7):1402-9. doi: 10.1016/j.bbapap.2013.01.018.

PMID:
23360763
15.

Synthesis and kinase inhibitory activity of novel substituted indigoids.

Beauchard A, Laborie H, Rouillard H, Lozach O, Ferandin Y, Le Guével R, Guguen-Guillouzo C, Meijer L, Besson T, Thiéry V.

Bioorg Med Chem. 2009 Sep 1;17(17):6257-63. doi: 10.1016/j.bmc.2009.07.051.

PMID:
19665384
16.

10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.

Falke H, Chaikuad A, Becker A, Loaëc N, Lozach O, Abu Jhaisha S, Becker W, Jones PG, Preu L, Baumann K, Knapp S, Meijer L, Kunick C.

J Med Chem. 2015 Apr 9;58(7):3131-43. doi: 10.1021/jm501994d.

17.

Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.

Drung B, Scholz C, Barbosa VA, Nazari A, Sarragiotto MH, Schmidt B.

Bioorg Med Chem Lett. 2014 Oct 15;24(20):4854-60. doi: 10.1016/j.bmcl.2014.08.054.

PMID:
25240617
18.

Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.

Rüben K, Wurzlbauer A, Walte A, Sippl W, Bracher F, Becker W.

PLoS One. 2015 Jul 20;10(7):e0132453. doi: 10.1371/journal.pone.0132453.

19.

Purpuroines A-J, halogenated alkaloids from the sponge Iotrochota purpurea with antibiotic activity and regulation of tyrosine kinases.

Shen S, Liu D, Wei C, Proksch P, Lin W.

Bioorg Med Chem. 2012 Dec 15;20(24):6924-8. doi: 10.1016/j.bmc.2012.10.014.

PMID:
23131412
20.

Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors.

Debdab M, Renault S, Lozach O, Meijer L, Paquin L, Carreaux F, Bazureau JP.

Eur J Med Chem. 2010 Feb;45(2):805-10. doi: 10.1016/j.ejmech.2009.10.009.

PMID:
19879673
Items per page

Supplemental Content

Support Center